Aldeyra’s sights set on November PDUFA

Aldeyra Therapeutics has a date at the FDA, specifically Nov. 23 for its dry eye disease drug.

After boldly claiming “approvability has been put to bed” last summer with a crossover study win, Aldeyra said Tuesday morning the US agency accepted its drug, reproxalap, for review.